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Abstract: Both male/female patients with Fabry disease (FD) may receive enzyme replacement
therapy (ERT). Previously published analyses of the Fabry Outcome Survey (FOS; Shire-sponsored)
database suggested gender differences in timing of ERT initiation. We assessed alignment of criteria
for ERT initiation in the Spanish adult population included in FOS with recommendations of a
Spanish national consensus. This retrospective analysis examined baseline clinical data of 88 adults
(49 females) enrolled in the FOS database up to August 2014. Thirty-five (39.8%) patients were
not receiving ERT: five (12.8%) males and 30 (61.2%) females. Baseline disease severity on the
FOS-derived Mainz Severity Score Index was lower in untreated males (median (interquartile range),
0.0 (0.0–1.0)) than treated males (TM; 15.0 (7.5–26.5)), and was similar in untreated and treated
females. The percentage of untreated females with at least one criterion for treatment initiation was
76.7% versus 100.0% of treated females (p = 0.0340) and 97.1% (p = 0.0210) of TM. In discordance
with Spanish consensus recommendations, a substantial number of females with evidence of FD
who might benefit from ERT have not yet initiated treatment. These results suggest unequal gender
perceptions with respect to ERT initiation in Spain.
Keywords: agalsidase alfa; enzyme replacement therapy; Fabry disease; Fabry Outcome Survey
(FOS); gender differences; Spain; women
1. Introduction
Fabry disease (FD) is a rare inherited X-linked metabolic disease secondary to reduction/absence of
lysosomal α-galactosidase A activity. As a result, a progressive accumulation of globotriaosylceramide
(Gb3) and related glycosphingolipids within lysosomes is believed to produce cellular changes that
progressively affect multiple organ systems, determining a natural disease evolution ranging from
an asymptomatic status in the first years of life to different clinical presentations with increasing
age. FD in adults has a wide variety of phenotypes, from the “classical” severe form in males to a
seemingly asymptomatic course in some females. Owing to the X-linked nature of the disease and the
potential for skewed X-chromosome inactivation, females can have normal α-galactosidase A activity in
plasma/leukocytes with variable signs and symptoms of FD [1,2]. Most heterozygous females develop
symptoms with vital organ involvement, usually later than males [1]. FD manifestations may include
neuropathic pain, gastrointestinal disturbances, angiokeratomas, hypohidrosis, kidney dysfunction,
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cardiac valve disease, cardiomyopathy and stroke, resulting in a reduction of health-related quality of
life (HRQoL) and an increased risk of premature mortality [3].
Treatment of FD in male/female (pediatric and adult) patients with enzyme replacement therapy
(ERT) has been shown to stabilize progressive multiorgan decline and improve clinical outcomes [1,4–6].
ERT reduces plasma and urine Gb3 and lyso-Gb3 levels, ameliorates early clinical symptoms such as
pain and gastrointestinal symptoms and improves heart rate variability and HRQoL [7–10]. At the
organ level, ERT reduces left ventricular mass (LVM) and ventricular wall thickness, and slows the
progression, or stabilizes, mild to moderate nephropathy as assessed by estimated glomerular filtration
rate (eGFR) [11–15]. Indeed, the pattern of mortality has changed since the introduction of ERT, from a
higher percentage of deaths by renal failure in males and cerebrovascular disease in females, to cardiac
disease in both genders [16]. Although few studies have been published specifically describing ERT
effects in female patients with FD [4,17–19], a direct comparison of agalsidase alfa ERT effectiveness
between male and female patients using data from the Fabry Outcome Survey (FOS) showed “that
women are as likely to respond to ERT as men” [20].
Several expert panel–derived guidelines for initiation of ERT have been proposed on the basis
of published evidence for efficacy and local health care system variations [21–23]. In Spain, a 2005
national consensus document set criteria for initiation of ERT in patients with FD independent of
patient gender [24]; an update of this became available in 2011 [25].
FOS, sponsored by Shire, is a global international multicenter registry of patients with a confirmed
diagnosis of FD who are receiving, or are candidates for, ERT with agalsidase alfa. Previously published
analyses of Spanish patients included in the FOS database suggested gender differences at the time
of ERT initiation [26,27]. The aim of our research was to assess the extent to which criteria for ERT
initiation in the Spanish adult population included in FOS align with recommendations of a national
consensus document.
2. Results
In August 2014, 88 Spanish adult patients from 28 hospital centers were included in FOS, of whom
49 (55.7%) were female. Overall median (interquartile range (IQR)) for age at symptom onset was
14 (10–25) years in males and 27 (16–39) years in females.
A total of 53 (60.2%) patients were receiving ERT, including 87.2% of males and 38.8% of females.
The groups studied comprised 34 treated males (TM; 38.6% of the total sample; 87.2% of all males), five
untreated males (UM; 5.7% of the total sample; 12.8% of all males), 19 treated females (TF; 21.6% of the
total sample; 38.8% of all females) and 30 untreated females (UF; 34.1% of the total sample; 61.2% of all
females). Baseline clinical characteristics are shown in Table 1.
Males and females receiving ERT at baseline began treatment at a median (IQR) age of
41.4 (33.2–50.0) years; age at treatment initiation was independent of gender, even when age at
symptom onset was different. Median (IQR) age of symptom onset was lower in TM (14.0 (10.0-25.0)
years) than in TF (30.5 (16.0-41.0) years; p = 0.027). The median (IQR) age at treatment initiation in TF,
47.7 (35.8–52.8) years, was not significantly different than the median (IQR) age at data extraction in UF,
45.7 (35.4–57.5) years (p = 0.910). FOS-Mainz Severity Score Index (MSSI) scores of treated male patients
were higher than those of untreated male patients, indicating greater disease severity in treated versus
untreated male patients. The median baseline FOS-MSSI score was not significantly different between
treated and untreated female patients. HRQoL, as measured by EuroQol 5-Dimensions (EQ-5D), was
assessed for only 3 of 30 (10%) UF, 6 of 19 (32%) TF and 11 of 34 (32%) TM.
The percentage of patients with proteinuria (recorded as “signs and symptoms” in the FOS
database; Table 1) was much lower in UF (16.7%) compared with TM (61.8%; p < 0.0001), and was
approximately half that seen in TF (36.8%; p = 0.1730). Analytical values for proteinuria (Table 1) were
present in 25.0% of UF, versus 70.6% (p = 0.0250) of TM and 54.5% (p = 0.2140) of TF. The percentage
of patients with eGFR <90 mL/min/1.73 m2 was 30.0% in UF, 36.8% in TF, 0% in UM and 52.9% in
TM (Table 1). Baseline microalbuminuria with a renal biopsy suggestive of FD was seen in 1 UF, 1 TF,
2 TM and in no UM. Left ventricular hypertrophy (LVH) recorded as “signs and symptoms” in the
FOS database was present in 36.8% of TF and 23.3% of UF (p = 0.3460).
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Table 1. Baseline clinical characteristics of Spanish patients with Fabry disease included in the FOS registry as of August 2014 by gender and treatment status.
Characteristic All All Treated TM TF UF UM
n (%) 1 88 (100.0) 53 (60.2) 34 (38.6) 19 (21.6) 30 (34.1) 5 (5.7)
Median (IQR) age at symptom onset (years) 20.0 (11.0–33.5)n = 48
20.0 (10.0–35.0)
n = 37
14.0 (10.0–25.0) 2
n = 23
30.5 (16.0–41.0)
n = 14
25.0 (16.0–32.0)
n = 11
0
n = 0
Median (IQR) age at data extraction (years) 46.6 (36.0–54.8)n = 88
47.1 (41.1–54.4)
n = 53
46.1 (38.2–52.1)
n = 34
53.1 (42.8–64.9)
n = 19
45.7 (35.4–57.5)
n = 30
33.1 (25.5–34.5)
n = 5
Median (IQR) age at ERT initiation (years) — 41.4 (33.2–50.0)n = 53
38.3 (30.2–46.6)
n = 34
47.7 (35.8–52.8)
n = 19 — —
Median (IQR) total FOS-MSSI score 9.5 (5.3–16.5)n = 88
14.0 (7.0–20.0)
n = 53
15.0 (7.5–26.5) 3
n = 34
11.0 (6.0–17.0)
n = 19
8.0 (4.5–10.0)
n = 30
0.0 (0.0–1.0)
n = 5
Median (IQR) EQ-5D index score 0.7 (0.5–0.8)n = 20
0.7 (0.3–0.8)
n = 17
0.8 (0.3–0.8)
n = 11
0.7 (0.3–0.7)
n = 6
0.8 (0.7–1.0)
n = 3
—
n = 0
Median (IQR) number of organs affected 4.0 (3.0–6.5)n = 84
5.0 (3.0–8.0)
n = 53
5.5 (3.0–8.0) 3
n = 34
5.0 (3.0–8.0)3
n = 19
4.0 (2.0–4.0)
n = 28
2.0 (1.0–3.0)
n = 3
Neuropathic pain, n (%) 1 32 (36.4) 23 (43.4) 14 (41.2) 9 (47.4) 9 (30.0) 0
eGFR < 90 mL/min/1.73 m2, n (%) 1 34 (38.6) 25 (47.2) 18 (52.9) 7 (36.8) 9 (30.0) 0
Proteinuria: signs or symptoms, n (%) 1 34 (38.6) 28 (52.8) 21 (61.8) 3 7 (36.8) 5 (16.7) 1 (20.0)
Proteinuria > 300 mg/24 h, n (%) 1 21 (51.2) 18 (64.3) 12 (70.6) 3 6 (54.5) 3 (25.0) 0
Dialysis, n (%) 1 7 (8.0) 7 (13.2) 7 (20.6) 2,3 0 0 0
Renal transplant, n (%) 1 7 (8.0) 7 (13.2) 7 (20.6) 2,3 0 0 0
LVH: signs or symptoms, n (%) 1 33 (37.5) 25 (47.2) 18 (52.9) 3 7 (36.8) 7 (23.3) 1 (20.0)
LVH based on LVM index ≥48 g/m2.7
(females) or ≥51 g/m2.7 (males), n (%) 1 15 (50.0) 13 (61.9) 10 (71.4)
3 3 (42.9) 2 (22.2) 0
Atrioventricular block, n (%) 1 1 (1.1) 1 (1.9) 0 1 (5.3) 0 0
Bundle branch block, n (%) 1 3 (3.4) 2 (3.8) 2 (5.9) 0 1 (3.3) 0
Arrhythmia, n (%) 1 4 (4.5) 4 (7.5) 4 (11.8) 0 0 0
Transient ischemic attack, n (%) 1 2 (2.3) 2 (3.8) 1 (2.9) 1 (5.3) 0 0
Stroke, n (%) 1 2 (2.3) 2 (3.8) 1 (2.9) 1 (5.3) 0 0
eGFR, estimated glomerular filtration rate; EQ-5D, EuroQol 5-Dimensions; ERT, enzyme replacement therapy; FOS, Fabry Outcome Survey; IQR, interquartile range; LVH, left
ventricular hypertrophy; LVM, left ventricular mass; MSSI, Mainz Severity Score Index; TF, treated female; TM, treated male; UF, untreated female; UM, untreated male; 1 Percentage
of total patients assessed; 2 Statistically significant difference versus TF (p < 0.05); 3 Statistically significant difference versus UF (p < 0.05).
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UF did not substantially differ from treated patients in disease characteristics such as pain or
other markers of renal and cardiac involvement. Neuropathic pain was present in 30.0% of UF,
with a distribution of median (IQR) Brief Pain Inventory (BPI) scores for worst (8.0 (8.0–8.0)), least
(2.5 (0.0–5.0)) or average (3.5 (0.0–7.0)) pain during the previous 24 h, or for pain intensity at the visit
(7.5 (7.0–8.0)) that did not notably differ from those in the other groups of patients. Median (IQR)
EQ-5D index score in UF (0.8 (0.7–1.0)) was similar to that in TF (0.7 (0.3–0.7)). A graphical comparison
of the proportion of patients by organs affected in TM, TF and UF is displayed in Figure 1.
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As a result, the percentage of UF fulfilling at least one criterion of the Spanish guidelines for
treatment initiation was 76.7%, which differed from the percentage of both TF (100%; p = 0.0340) and
TM (97.1%; p = 0.0210; Table 2). The presence of other criteria was as follows: 30.0% of UF met pain
criteria (versus 47.4% of TF (p = 0.2420) and 41.2% of TM (p = 0.4370)) and 23.3% of UF met cardiac
criteria (versus 52.6% of TF (p = 0.0630) and 55.9% of TM (p = 0.0110)). Further, 43.3% of UF met
renal criteria (versus 57.9% of TF (p = 0.3870) and 82.4% of TM (p = 0.0020)). Distribution of patients
according to the criteria is shown in Table 2.
Table 2. Description of the distribution of Spanish patients included in the FOS registry in August 2014
according to the criteria for treatment initiation stated in the Spanish national consensus of 2005 [24],
updated in 2011 [25], by gender and treatment status.
Treatment Criteria All All Treated TM TF UF
n (%) 1 88 (100.0) 53 (60.2) 34 (3 .6) 19 (21 6 0 (34.1)
Fulfilling ≥1 criteria from
all parameters, n (%) 76 (86.4) 52 (98.1) 33 (97.1)
2 19 (100.0) 2 23 (76.7)
Pain criteria 32 (36.4) 23 (43.4) 14 (41.2) 9 (47.4) 9 (30.0)
Renal criteria 53 (60.2) 39 (73.6) 28 (82.4) 2 11 (57.9) 13 (43.3)
Cardiac criteria 37 (42.0) 29 (54.7) 19 (55.9) 2 10 (52.6) 7 (23.3)
Neurological criteria 2 (2.3) 2 (3.8) 1 (2.9) 1 (5.3) 0
FOS, Fabry Outcome Survey; TF, treated female; TM, treated male; UF, untreated female; 1 Percentage of total
patients; 2 Statistically significant difference versus UF (p < 0.05).
Int. J. Mol. Sci. 2016, 17, 1965 5 of 11
3. Discussion
The study of rare diseases is intrinsically impaired by their low prevalence, making a complete
picture of clinical characteristics and management difficult to ascertain. Therefore, global multicenter
registries are an essential tool for the study of rare diseases; the FOS registry is one of the largest
disease-specific registries of patients with FD. Although inter-center variations in data collection
procedures are common, they are addressed by a common protocol that defines the standard data
to be collected and unifies them into a single database for analysis. The noninterventional nature of
this research method permits the observation of clinical practice variability in management of FD that
may lead to detection of unmet needs and disparities or divergences from current recommendations.
This paper describes a set of Spanish adult patients at inclusion in FOS according to treatment status
and gender. One of the objectives was to present clinical characteristics of this population and to
compare the treatment status with the recommendations from a national consensus panel to explore
deficiencies in ERT access.
The relatively short period since ERT introduction in 2001, the low prevalence of FD and
its slow progression hampers understanding of long-term and patient-related outcomes and
mortality. Consequently, international guidelines for ERT initiation are mostly based on expert
panel recommendations. As a result, guidelines vary from one country to another, particularly in
management of heterozygous females and children [21]. Spanish guidelines existing at the time
when the patients entered FOS did include the definitions and criteria from international guidelines,
but did not differentiate patients by age or gender regarding when it should be advisable to start
ERT [24]. However, the presence of one major criterion in females is consistent with the international
consensus document regarding indications for ERT in females when progression of organ involvement
is detected [23]. Spanish guidelines were updated in 2011 [25], maintaining the main criteria to start
ERT, but refining some definitions and indications for treatment initiation in light of international
consensus. In our opinion, the fact that the main criteria to start ERT were the same in the 2011 update
as those proposed in 2005, but were more thoroughly defined and less vague in the update, may have
increased the number of patients deemed as qualifying for ERT, but without any relevant effect on the
number of patients not receiving ERT, especially females; this is one of the most striking findings of
our work.
The gender differences observed in access to ERT according to existing guidelines confirm
that a proportion of female patients with FD fulfill criteria for ERT initiation, but are not receiving
treatment. This finding has previously been suggested in published analyses of the Spanish patients in
FOS [26,27], all patients in FOS [20] and other studies from different registries [28–32]. Disease rarity,
misconceptions about their carrier status and gender have been proposed as the main drivers for the
differential access to ERT for females with FD [33]. Evolving knowledge of the natural history of FD
and its management with ERT has changed the consideration of heterozygous females from obligate
carriers, mostly asymptomatic or with mild disease, to patients with important clinical features and
time-dependent disease progression without ERT [30,34,35]. Evidence from the literature suggests
that females are referred less often for diagnostic interventions and treated less aggressively than
males [33]. Furthermore, disparities in treatment between genders have been consistently identified
for heart [36] and kidney diseases [31,37], among others [32].
The fact that there were no differences in the number of affected organs between UF and TF or
between UF and TM suggests the multisystem nature of the disease in both genders in our patients.
There was no significant difference between UF and TF in FOS-MSSI scores, and 76.7% of UF fulfilled
at least one criterion for ERT initiation. Considered independently, 60.0% of UF fulfilled one renal
criterion, most frequently renal impairment (eGFR < 90 mL/min/1.73 m2 in 30.0%). This is similar
to values reported for UF in other registries (e.g., 55% in Ortiz et al.) [28], and similar or slightly
lower than those reported in the literature for combined TF and UF (e.g., 58% in Wang et al. [30],
62.5% in Wilcox et al. [38]). Proteinuria (recorded as a sign/symptom) was observed in 17% of UF,
similar to the 16% reported for the whole group of Spanish females included in FOS in 2009 [26].
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A recent review noted that progressive nephropathy is prominent in FD and although males are more
profoundly affected than females, the authors concluded that both males and females should initiate
ERT if they have evidence of renal involvement [39]. More than half of UF met the criteria to start
ERT based on cardiac involvement. These included LVM index as the major driver, atrioventricular
block and LVH. The observed LVH frequency does differ from some reports for all females in previous
publications [30,34]; however, prevalence of LVH is age dependent and is higher in older populations.
Recently, Hopkin et al. presented data from the Fabry Registry showing that delayed ERT, as well
as having experienced a previous clinical event (cardiac, renal or cerebrovascular) before ERT start,
are risk factors for an unfavorable evolution and the appearance of new clinical events under ERT, in
male and female patients alike [40]. In accordance with this, the absence of timely ERT initiation in
female as well as in male patients showing cardiac or renal involvement of FD may jeopardize their
clinical evolution. This clearly applies to patients with classic FD; however, atypical milder, later-onset
phenotypes have been associated with variant mutations, including cardiac and cerebrovascular
variants [41–44].
Recently, Lenders et al. published the findings of a multicenter German study with 224 genetically
confirmed adult female patients with FD [45], investigating their current ERT status at the time of their
last visit to analyze whether patients were treated in accordance with current European FD guidelines
(class I and IIA/B recommendations) [23]. It is noteworthy that these recommendations are quite
similar to the 2011 update of the Spanish recommendations [25]. Lenders et al. found in their cohort
that one-third of German females without ERT fulfilled indications for starting it [45]. Unlike the
population in the German cohort where TF were older than UF, in our patients we did not see any
differences in age between UF at data collection and TF at ERT start. In addition, in our patients as
well as in the German cohort, both TF and UF showed a significant number of organs affected by the
disease as an expression of multisystemic involvement. Moreover, the main organ manifestations seen
in German TF were cardiac and, to a lesser extent, renal [45]; similarly, in our Spanish TF patients,
cardiac involvement was somewhat more frequently seen than renal involvement. It thus appears
that there are some differences in the management of female compared with male patients with FD in
clinical practice in Germany as well as in Spain.
Two limitations of our research should be mentioned. First, the numbers of patients overall, and
especially in the various subgroups, are quite small, with missing data for some parameters. The data
were collected from an observational registry that was not specifically designed to assess gender
differences in ERT initiation. Together with the large number of evaluated outcomes, these factors
might have reduced the power and robustness of the statistical tests. Selection bias is a recognized
limitation of registry studies and not all patients in our sample had complete data, a reflection of
real-world clinical practice.
The second limitation of our study could be the use of ERT initiation criteria according to an
updated version of the 2005 recommendations. This update might have increased the sensitivity of
cardiac and, to a lesser extent, renal criteria for detecting treatment candidates and, consequently, may
have modified the classification for a certain number of patients. It should be noted that these data
were collected more than three years after the last recommendations update; therefore, physicians
should have had enough time to adopt the latest criteria. In our opinion, failure to do so reflects
nonadherence to recommendations regardless of the proposed criteria, rather than the effect of other
factors. According to our current knowledge, some female patients with mild renal involvement
(e.g., with microalbuminuria and a slight decrease in eGFR to 80–90 mL/min/1.73 m2) could have
slow clinical progression and without objective signs of other organ damage (cardiac, central nervous
system, pain or gastrointestinal symptoms), a personalized approach is warranted and ERT could
be delayed with careful and continuous follow-up. Additionally, some of the assessments were not
available for all patients (e.g., laboratory results for proteinuria, some echocardiographic assessments
and EQ-5D or BPI score).
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Nonetheless, from our point of view, the current study is important because it addresses
differences based on gender regarding ERT initiation in Spain, somewhat similar to that observed in
another European country. As with many diseases, clinicians in the real-world setting derive their
best practices from both clinical practice guidelines and their own clinical experience and impressions.
There is an ongoing need in the medical community for greater and more widespread knowledge
regarding FD and other rare diseases to illuminate our current understanding that heterozygous
females with FD may have substantial disease effects. In turn, this can only enhance our efforts to offer
the best standard of care for both men and women with FD. Disease registry analyses, such as the
current one, can offer valuable insights into real-world disease management.
4. Materials and Methods
4.1. Design
This was a retrospective analysis of baseline clinical data of adult patients with FD who were
managed in Spanish centers and enrolled in the FOS database up to August 2014.
4.2. Study Population
Characteristics of the FOS registry that started data collection in 2001 have been described
elsewhere [46,47]. Briefly, the FOS registry collects standardized information from patients who are
managed at participating centers and provide signed informed consent. FOS has been approved by
the ethics committee/institutional review board of all participating centers and all procedures were
in accordance with the Declaration of Helsinki of 1975, revised in 2013. Information obtained during
routine clinical follow-up includes baseline and clinical laboratory data plus additional information on
patient-reported outcomes collected through questionnaires (e.g., pain and HRQoL) [46]. Additionally,
disease severity is assessed through the FOS-MSSI, an adaptation of the MSSI to a binary format data
input [48,49].
4.3. Study Measures
The 2005 Spanish national consensus document stated that ERT should be initiated for FD
immediately upon presentation of any one of the following signs or symptoms (major criteria) [24]:
severe neuropathic pain, nephropathy (proteinuria >300 mg/24 h in adults or >5 mg/kg/24 h in
children; eGFR < 80 mL/min/1.73 m2; renal biopsy), cardiac disease (LVH, ischemic heart disease
or arrhythmias) or cerebrovascular disease (clinical or neuroradiological signs). Additionally, ERT
initiation may be considered when at least two of the following FD symptoms are present (minor
criteria): hypoacusia or vertigo interfering with HRQoL, gastrointestinal manifestations, asthenia,
episodic fever, osteoarticular disease, growth delay, microalbuminuria or mild acroparesthesia.
In the 2011 update, the former criteria were refined regarding main organ involvement, and
it was emphasized that such criteria should be the same for every patient regardless of
gender [25]. Specifically, the eGFR criterion was raised to 90 mL/min/1.73 m2, more specific
electrocardiographic and echocardiographic criteria were considered for diagnosis of cardiac
involvement and microalbuminuria was “upgraded” from a minor to a major criterion, but with
a renal biopsy with FD findings [25].
eGFR was calculated with serum creatinine values adjusted (if necessary) by the analytical method
used at each center to achieve uniformity [50]. LVH was considered when LVM index was ≥51 g/m2.7
in males or ≥48 g/m2.7 in females. LVM index was determined by standard M-echocardiography
at each participating center and adjusted for height using the Devereux formula [51]. HRQoL was
assessed through the EuroQol Group’s measure of health status (EQ-5D) [52], using a descriptive
system of five categorical dimensions, a visual analog scale ranging from 0 (death) to 100 (full health)
and a derived tariff based on population weights from 0–1 with the same extreme anchors [53].
The MSSI consists of four sections covering various signs and symptoms of the disease (general,
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neurological, cardiovascular and renal), weighted in accordance with their contribution to morbidity.
Hence, a global score was obtained to enable patient classification according to disease severity.
4.4. Statistical Analyses
Descriptive and analytical analyses were performed for the overall sample and for subgroups
created according to gender and ERT status: TM, TF, UM and UF. Categorical variables were
described by their frequency and percentage. Continuous variables were described by median and
IQR (IQR = Q1 − Q3). Comparisons between two independent samples were made with Wilcoxon
rank-sum test for continuous variables and Fisher’s exact test for categorical variables.
5. Conclusions
These results suggest gender differences in initiation of ERT in Spain. With reference to
recommendations of a Spanish consensus on FD, a substantial number of females with evidence
of FD may benefit from ERT but have not yet initiated treatment. The ERT initiation delay in female
patients who fulfill the criteria for ERT initiation results in these patients missing the full benefits of
treatment and might put them at risk of FD complications with associated morbidity and mortality.
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